ClinicalTrials.Veeva

Menu

PT/INR Reference Interval IN Healthy Volunteers (REF01)

M

Microvisk Technologies

Status

Completed

Conditions

Healthy

Study type

Observational

Funder types

Industry

Identifiers

NCT02319109
2011/REF01

Details and patient eligibility

About

This is a prospective, single-center study in healthy volunteers to establish a PT/INR reference interval for the Microvisk International Normalized Ratio (INR) Test System. The primary objective of this study is to establish the reference interval for the measurement of prothrombin time (PT/INR) using the Microvisk INR Test System. The second objective is to evaluate the safety of the device.

Full description

Healthy volunteers who meet eligibility criteria, have been fully informed and provided written informed consent will be enrolled into this study. Each participant will be required to donate up to 3 finger stick samples for testing on one occasion. The maximum trial duration for each participant is one visit/occasion. This will be followed by a standard venipuncture for (1) a neutral tube (Red Top) for analysis by the on-test method, (1) one sodium citrate tube (Blue Top) for analysis by the comparative/reference laboratory method. Sample collection will take place within the clinic session. The maximum trial duration for each participant is one clinic session.

Enrollment

154 patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  1. Subject is considered a healthy volunteer
  2. Subject is male or female, over 18 years of age
  3. Subject is informed and has been given ample time and opportunity to think about his/her participation and has given his/her written informed consent
  4. Subject agrees to have blood drawn (venipuncture) and finger stick

Exclusion criteria

  1. Subject is unable to give informed consent
  2. Subject is less than 18 years of age
  3. Female subject is pregnant
  4. Subject is on anticoagulant medication or other medication known to affect PT/INR assessment (e.g., warfarin, heparin) for a minimum of 28 days before enrolling in the trial
  5. Subject has a medical condition known to affect PT/INR (e.g. vitamin K deficiency, disseminated intravascular coagulation, liver disease, decreased or defective factor I, II, V, VII, or X)
  6. Subject has already taken part in the study

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems